Text Size
21 studies found for:    " March 14, 2012":" April 13, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Modify this search | How to Use Search Results

Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Cancel
Rank Status Study
1 Active, not recruiting Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: darunavir/cobicistat/emtricitabine/GS-7340;   Drug: darunavir + cobicistat + emtricitabine/tenofovir df
2 Recruiting Project RETAIN: Providing Integrated Care for HIV-Infected Crack Cocaine Users
Conditions: HIV;   AIDS;   Substance Abuse
Intervention: Behavioral: Retention Clinic
3 Terminated The Mochudi Prevention Project ART Protocol
Condition: HIV Infections
Intervention: Drug: highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine
4 Recruiting Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
Condition: HIV Infection
Interventions: Drug: Tenofovir, Emtricitabine, Lopinavir/r;   Drug: Tenofovir, Emtricitabine, Raltegravir
5 Active, not recruiting Part A: Drug Interaction Study of GS-7977 and Antiretroviral Therapy(ART) Combinations in Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) Co-infected Patients. Part B: Phase 2, Open-Label Study to Investigate Efficacy and Safety of GS-7977 for 12 Weeks in HIV/HCV Co-infected Patients.
Conditions: Hepatitis C;   HIV
Interventions: Drug: GS-7977;   Drug: Efavirenz (EFV);   Drug: Tenofovir (TDF);   Drug: Emtricitabine (FTC);   Drug: Atazanavir/ritonavir (ATV/r);   Drug: Zidovudine (ZDV);   Drug: Lamivudine (3TC);   Drug: Darunavir/ritonavir (DRV/r);   Drug: Raltegravir (RAL);   Drug: Ribavirin (RBV);   Drug: Peginterferon Alfa 2a (PEG)
6 Active, not recruiting Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
Condition: HIV Infections
Interventions: Biological: GEO-D03 DNA vaccine;   Biological: MVA/HIV62B (MVA62B) vaccine;   Biological: Placebo for GEO-D03 DNA;   Biological: Placebo for MVA62B:
7 Recruiting Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-MAG vaccine;   Biological: IL-12 pDNA adjuvant;   Biological: VSV HIV gag vaccine;   Biological: Placebo
8 Completed A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: DTG;   Drug: BCV;   Drug: TVR
9 Active, not recruiting Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg twice daily;   Drug: dolutegravir placebo twice daily;   Drug: Open-label dolutegravir 50mg twice daily
10 Recruiting Intervention to Improve Engagement in Care Among Newly Diagnosed HIV-positive Men
Conditions: HIV;   Patient Compliance
Interventions: Behavioral: Positive Choices;   Behavioral: Personalized Cognitive Counseling
11 Recruiting Cell Phone Messaging to Improve Communication of Critical Laboratory Results to Patients in Rural Uganda
Conditions: HIV;   Tuberculosis
Intervention: Other: Cellular Phone Text Message Formats
12 Recruiting Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
Condition: HIV
Intervention: Drug: Tesamorelin for injection
13 Completed Experimental Analysis of HIV Risk Assessment Reactivity in South African Clinics
Condition: HIV Prevention and Assessment Reactivity
Interventions: Behavioral: Detailed baseline interview, enhanced HIV intervention;   Behavioral: General baseline interview, enhanced HIV intervention;   Behavioral: No baseline interview, enhanced HIV intervention;   Behavioral: Detailed baseline interview, standard of care intervention;   Behavioral: General baseline interview, standard of care intervention;   Behavioral: No baseline interview, standard of care intervention
14 Recruiting A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy
Condition: HIV-associated Myelopathy
Interventions: Drug: Intravenous Immunoglobulin;   Drug: Placebo
15 Recruiting The Rilpivirine Cerebrospinal-fluid (CSF) Study
Condition: HIV
Intervention: Drug: Rilpivirine
16 Enrolling by invitation Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV
Conditions: Tobacco Use Cessation;   Tobacco Cessation;   Tobacco Use Disorder;   Tobacco Dependence;   Tobacco-Use Disorder;   Virus, Human Immunodeficiency
Interventions: Behavioral: Web-Based Tailored Smoking Cessation Intervention;   Behavioral: Standard of Care
17 Recruiting Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution
Conditions: Substance-related Disorders;   HIV Risk Behavior
Interventions: Behavioral: Therapeutic Workplace;   Drug: Methadone;   Drug: Buprenorphine
18 Recruiting Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome
Conditions: Immune Reconstitution Inflammatory Syndrome;   Opportunistic Infections
Intervention:
19 Not yet recruiting Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection
Condition: Cryptococcal Infection Disseminated
Interventions: Drug: Flucytosine and fluconazole;   Drug: Fluconazole
20 Recruiting Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
Conditions: Anal Cancer;   Cervical Cancer;   Lung Cancer;   Lymphoma;   Nonneoplastic Condition
Interventions: Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: medical chart review
To Top

Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results
† Indicates status has not been verified in more than two years